Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLS-5700 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | EXPERIMENTAL | Placebo at 0 mg DNA/dose |
| GLS-5700 | EXPERIMENTAL | GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus |
| Name | Type | Description |
|---|---|---|
| GLS-5700 | BIOLOGICAL | GLS 5700 at 2 mg DNA/dose |
| Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Age 18-65 years; * Able to provide consent to participate and having signed an Informed Consent Form (ICF); * Able and willing to comply with all study procedures; * Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier me...
GLS-5700 is an investigational vaccine candidate developed by Inovio Pharmaceuticals, Inc. for protection against Zika virus infection. It is a synthetic DNA-based product designed to be administered to healthy adults. GLS-5700 has been studied in a Phase 1 clinical trial and is not approved for any indication.
GLS-5700 is being developed for the prevention of Zika virus infection. It is intended for use in healthy adults, including those who may have prior exposure to related flaviviruses such as dengue. The candidate has been evaluated in a Phase 1 trial in Puerto Rico.
GLS-5700 is being developed by Inovio Pharmaceuticals, Inc., a biotechnology company traded on the NASDAQ under the ticker symbol INO. Inovio is the sponsor of the clinical program for this Zika vaccine candidate.
GLS-5700 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not approved by the FDA or any regulatory authority. As an investigational product, it remains in early-stage clinical testing.
GLS-5700 has been studied in a single Phase 1 clinical trial, NCT02887482, titled "GLS-5700 in Dengue Virus Seropositive Adults." The trial enrolled 160 healthy adult participants in Puerto Rico and has been completed. It was randomized, double-blind, and controlled.